USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway

[1]  Yvonne N. Fondufe-Mittendorf,et al.  The multifaceted role of PARP1 in RNA biogenesis , 2020, Wiley interdisciplinary reviews. RNA.

[2]  A. Mangerich,et al.  The Nucleolus and PARP1 in Cancer Biology , 2020, Cancers.

[3]  Ziyan Wang,et al.  USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition via Wnt/β-Catenin Pathway , 2020, Frontiers in Pharmacology.

[4]  J. Vadgama,et al.  Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer , 2020, Cancers.

[5]  N. Garg,et al.  PARP1-cGAS-NF-κB pathway of proinflammatory macrophage activation by extracellular vesicles released during Trypanosoma cruzi infection and Chagas disease , 2020, PLoS pathogens.

[6]  C. D. Dela Cruz,et al.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention. , 2020, Clinics in chest medicine.

[7]  Qin Liu,et al.  Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway , 2020, Acta pharmaceutica.

[8]  Guofang Zhao,et al.  Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling , 2020, Anti-cancer drugs.

[9]  A. Tan.  Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) , 2020, Thoracic cancer.

[10]  A. Kunnumakkara,et al.  TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-κB Signaling Cascade , 2019, Biomolecules.

[11]  F. Oltulu,et al.  Autophagy and mTOR pathways in mouse embryonic stem cell, lung cancer and somatic fibroblast cell lines , 2019, Journal of cellular biochemistry.

[12]  N. Donato,et al.  Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells , 2019, Oncotarget.

[13]  A. K. Murugan.  mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.

[14]  H. Hua,et al.  Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.

[15]  Yili Yang,et al.  Ubiquitin specific peptidase 5 regulates colorectal cancer cell growth by stabilizing Tu translation elongation factor , 2019, Theranostics.

[16]  S. Jonna,et al.  Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. , 2019, Discovery medicine.

[17]  Zhenyu Li,et al.  Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K/Akt/mTOR pathway , 2019, Anti-cancer drugs.

[18]  Olga I Lavrik,et al.  Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins , 2019, Nucleic acids research.

[19]  Honggang Zhou,et al.  USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma , 2019, Theranostics.

[20]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[21]  T. Zeng,et al.  PARP1-siRNA suppresses human prostate cancer cell growth and progression. , 2018, Oncology reports.

[22]  B. Halmos,et al.  Biomarker use in lung cancer management: expanding horizons. , 2018, Biomarkers in medicine.

[23]  Fan Yang,et al.  Overexpression of USP5 contributes to tumorigenesis in non-small cell lung cancer via the stabilization of β-catenin protein. , 2018, American journal of cancer research.

[24]  Jie He,et al.  Epidemiology of Lung Cancer. , 2016, Surgical oncology clinics of North America.

[25]  I. Wistuba,et al.  Diagnosis and Molecular Classification of Lung Cancer. , 2016, Cancer treatment and research.

[26]  Haixiang Yu,et al.  The Clonal Evolution and Therapeutic Approaches of Lung Cancer , 2014, Cell Biochemistry and Biophysics.

[27]  E. Thunnissen,et al.  Molecular sputum analysis for the diagnosis of lung cancer , 2013, British Journal of Cancer.

[28]  P. Bunn.  Worldwide overview of the current status of lung cancer diagnosis and treatment. , 2012, Archives of pathology & laboratory medicine.

[29]  R. Krahe,et al.  PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis , 2012, Molecular carcinogenesis.

[30]  L. Chirieac,et al.  Advances in treatment of lung cancer with targeted therapy. , 2012, Archives of pathology & laboratory medicine.

[31]  M. Louw,et al.  Immunochemistry and Lung Cancer: Application in Diagnosis, Prognosis and Targeted Therapy , 2011, Oncology.

[32]  D. Lane,et al.  Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53* , 2009, Journal of Biological Chemistry.

[33]  Bettina Martini.  [Lung cancer--epidemiology, prognosis and therapy]. , 2006, Medizinische Monatsschrift fur Pharmazeuten.

[34]  Pierre P Massion,et al.  The molecular basis of lung cancer: molecular abnormalities and therapeutic implications , 2003, Respiratory research.